A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma.

Trial Profile

A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Retaspimycin (Primary)
  • Indications Liposarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Infinity Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Planned initiation date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 07 Sep 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top